DOCSLIB.ORG

Combined Index to USP 42 and NF 37, Volumes 1–5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Combined Index to USP 42 and NF 37 Abaca-Acety I-1 Combined Index to USP 42 and NF 37, Volumes 1–5 Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 42±NF 37. This index is repeated in its entirety in each volume. 1±2430 Volume 1 2431±4680 Volume 2 4681±6046 Volume 3 6047±7104 Volume 4 7105±8582 Volume 5 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, and tramadol hydrochloride oral A dextromethorphan, and suspension, 4415 pseudoephedrine, capsules containing at Acetanilide, 6070 Abacavir least three of the following, 53 Acetate oral solution, 21 and (salts of) chlorpheniramine, methyl, 6116 sulfate, 25 dextromethorphan, and Acetate buffer, 6083 tablets, 22 pseudoephedrine, oral powder TS, 6164 and lamivudine tablets, 23 containing at least three of the Acetazolamide, 75 Abiraterone following, 55 for injection, 75 acetate, 27 and (salts of) chlorpheniramine, oral suspension, 77 acetate tablets, 28 dextromethorphan, and tablets, 78 Absolute pseudoephedrine, oral solution Acetic acid, 5553, 6070 alcohol, 6071 containing at least three of the ammonium acetate buffer TS, 6164 ether, 6070 following, 58 diluted, 5553, 6070, 6098 Absorbable and (salts of) chlorpheniramine, double-normal (2 N), 6177 dusting powder, 1538 dextromethorphan, and glacial, 78, 6070, 6107 gelatin film, 2045 pseudoephedrine, tablets containing at glacial, TS, 6164, 6168 gelatin sponge, 2045 least three of the following, 60 and hydrocortisone otic solution, 2185 surgical suture, 4148 chlorpheniramine maleate, and irrigation, 79 Absorbent dextromethorphan hydrobromide metaphosphoric, TS, 6170 cotton, 6070 tablets, 62 otic solution, 79 gauze, 2043 and codeine phosphate capsules, 64 strong, TS, 6164 Acacia, 5551 and codeine phosphate oral solution, 65 1 M TS, 6164 syrup, 5551 and codeine phosphate oral suspension, 2 M TS, 6164 Acamprosate calcium, 30 66 Acetic acid in peptides, 6669 Acarbose, 32 and codeine phosphate tablets, 68 0.008 M Acetic acid TS, 6164 tablets, 33 dextromethorphan hydrobromide, 0.3 N Acetic acid TS, 6164 Acebutolol hydrochloride, 35 doxylamine succinate, and Acetic anhydride, 6070 capsules, 37 pseudoephedrine hydrochloride oral Acetohydroxamic acid, 80 Acepromazine maleate, 38 solution, 69 tablets, 81 injection, 39 and diphenhydramine citrate tablets, 71 Acetone, 5554, 6070 tablets, 40 diphenhydramine hydrochloride, and anhydrous, 6070 Acesulfame potassium, 5552 pseudoephedrine hydrochloride tablets, neutralized, 6070, 6164, 6166 Acetal, 6070 72 Acetonitrile, 6070 Acetaldehyde, 6070 and hydrocodone bitartrate tablets, 2176 spectrophotometric, 6070 TS, 6164 isometheptene mucate, and Acetophenone, 6070 Acetaldehyde ammonia trimer trihydrate, dichloralphenazone capsules, 2377 p-Acetotoluidide, 6070 6070 and oxycodone capsules, 3313 Acetylacetone, 6070 Acetaminophen, 40 and oxycodone tablets, 3315 Acetyl chloride, 6070 aspirin and caffeine tablets, 51 and pentazocine tablets, 3433 Acetylcholine chloride, 82, 6071 Index and aspirin tablets, 49 and pseudoephedrine hydrochloride for ophthalmic solution, 82 butalbital and caffeine capsules, 629 tablets, 73 Acetylcysteine, 83 butalbital and caffeine tablets, 630 oral solution, 43 Acetylcysteine and caffeine tablets, 52 for effervescent oral solution, 44 compounded solution, 84 capsules, 42 suppositories, 44 and isoproterenol hydrochloride inhalation oral suspension, 45 solution, 85 tablets, 47 extended-release tablets, 48 I-2 Acety-Alumi Combined Index to USP 42 and NF 37 Acetylcysteine (continued) Agar, 5557, 6071 pyrogallol TS, 6173 solution, 84 Agarose, 6071 sodium hydrosulfite TS, 6164 N-Acetylglucosamine, 4701 Air, medical, 101 Alkaline borate buffer, 6083 3-Acetylthio-2-methylpropanoic acid, 6071 Air-helium certified standard, 6071 Alkaline cupric tartrate TS, 6164 Acetyltributyl citrate, 5555 Alanine, 102, 4704 Alkyl (C12-15) benzoate, 5563 Acetyltriethyl citrate, 5555 L-Alanyl-L-glutamine, 4704 Alkylphenoxypolyethoxyethanol, 6072 N-Acetyltyrosine, 4702 Albendazole, 103 Allantoin, 131 N-Acetyl-L-tyrosine ethyl ester, 6071 oral suspension, 103 Allopurinol, 132 Acid tablets, 104 oral suspension, 134 acrylic, 6071 Albumen TS, 6164 tablets, 134 alpha lipoic, 5066 Albumin Allyl isothiocyanate, 135 dehydroacetic, 5694 bovine serum, 6071 Almond oil, 5563 ferric chloride TS, 6164 human, 105 Almotriptan ferrous sulfate TS, 6164 rAlbumin human, 5558 tablets, 138 Folic, compounded oral soultion, 1980 Albuterol, 105 Almotriptan malate, 136 iminodiacetic, 6111 sulfate, 110 Aloe, 140 stannous chloride TS, 6164 tablets, 106 Alpha stannous chloride TS, stronger, 6164 extended-release tablets, 107 lipoic acid, 5066 Acid-neutralizing capacity 〈301〉, 6588 Alclometasone dipropionate, 111 Alpha-chymotrypsin, 6072 Acidulated phosphate and sodium fluoride cream, 112 Alpha cyclodextrin hydrate, 6072 topical solution, 4036 ointment, 113 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Acitretin, 86 Alcohol, 114, 6071 6072 capsules, 87 70 percent, 80 percent, and 90 percent, Alphanaphthol, 6072 Statistical tools for procedure validation 6071 Alphazurine 2G, 6158 〈1210〉, 7126, 7524, 7998 absolute, 6071 Alprazolam, 141 Acrylic acid, 6071 aldehyde-free, 6072 oral suspension, 142 Activated alpha-(2-(methylamino)ethyl)benzyl, 6072 tablets, 143 alumina, 6071 amyl, 6072 extended-release tablets, 145 charcoal, 905, 6071 tert-amyl, 6072, 6075, 6112 orally disintegrating tablets, 149 magnesium silicate, 6071 butyl, 5602 Alprenolol hydrochloride, 6072 Acyclovir, 89 dehydrated, 116, 6072, 6093 Alprostadil, 151 capsules, 90 dehydrated isopropyl, 6072 injection, 153 for injection, 91 denaturated, 6072 Alteplase, 154 ointment, 92 denaturated, TS, 6167 for injection, 157 oral suspension, 93 determination 〈611〉, 6776 Alternative microbiological sampling methods tablets, 94 in dextrose injection, 118 for nonsterile inhaled and nasal products Adamantane, 6071 diluted, 5560, 6072 〈610〉, 6774 Adapalene, 95 injection, dehydrated, 117 Altretamine, 160 gel, 97 isobutyl, 6072 capsules, 161 Ademetionine disulfate tosylate, 4703 isopropyl, 6072 Alum, 6072, 6073 Adenine, 98 methyl, 6072 ammonium, 162, 6073 sulfate, 6071 neutralized, 6072, 6121 potassium, 163, 6131 Adenosine, 99 phenol TS, 6164 Alumina, 6073 injection, 100 n-propyl, 6072 activated, 6071, 6073, 6076 Adipic acid, 5556, 6071 rubbing, 119 anhydrous, 6073 Admissions secondary butyl, 6072 aspirin, codeine phosphate, and magnesia to NF 36, 5538 tertiary butyl, 6072 tablets, 398 to USP 41, xxix Alcoholic aspirin, and magnesia tablets, 391 ammonia TS, 6164 aspirin, and magnesium oxide tablets, 393 mercuric bromide TS, 6164 magnesia, and calcium carbonate potassium hydroxide TS, 6164 chewable tablets, 167 potassium hydroxide TS 2, 6173 magnesia, calcium carbonate, and Aerosol TS, 6164 simethicone chewable tablets, 168 Bacitracin and polymyxin B sulfate topical, Alcoholic potassium hydroxide magnesia, and calcium carbonate oral 460 0.2 N VS, 6177 suspension, 165 Benzocaine, butamben, and tetracaine Alcoholometric table, 6284 magnesia, and simethicone oral hydrochloride topical, 506 Aldehyde dehydrogenase, 6072 suspension, 170 Benzocaine and menthol topical, 511 Alendronate sodium, 120 magnesia, and simethicone chewable Benzocaine topical, 496 tablets, 121 tablets, 172 Fluticasone propionate and salmeterol Alfadex, 5561 and magnesia oral suspension, 164 inhalation, 1960 Alfentanil and magnesia tablets, 165 Fluticasone propionate inhalation, 1943 hydrochloride, 123 magnesium carbonate, and magnesium Inhalation and nasal drug products: injection, 124 oxide tablets, 175 aerosols, sprays, and powdersÐ Alfuzosin hydrochloride, 125 and magnesium carbonate oral suspension, performance quality tests 〈601〉, 6746 extended-release tablets, 126 173 Isoproterenol sulfate inhalation, 2388 Alginates assay 〈311〉, 6589 and magnesium carbonate tablets, 174 Lidocaine topical, 2568 Alginic acid, 5562 and magnesium trisilicate oral suspension, Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 6072 176 topical, 3564 Alkaline and magnesium trisilicate tablets, 177 Povidone±iodine topical, 3607 cupric citrate TS, 6164 Aluminon, 6073 Index Thimerosal topical, 4310 cupric citrate TS 2, 6164 Aluminum, 6073 Tolnaftate topical, 4390 cupric iodide TS, 6164 acetate topical solution, 178 Triamcinolone acetonide topical, 4445 mercuric-potassium iodide TS, 6164 chloride, 178 phosphatase enzyme, 6072 chlorohydrate, 179 picrate TS, 6164 chlorohydrate solution, 180 Combined Index to USP 42 and NF 37 Alumi-Ammon I-3 Aluminum (continued) 4-Aminoantipyrine, 6073 Amlodipine and atorvastatin chlorohydrex polyethylene glycol, 181 Aminobenzoate tablets, 263 chlorohydrex propylene glycol, 182 potassium, 221 Amlodipine besylate, 280 dichlorohydrate, 182 potassium capsules, 223 tablets, 281 dichlorohydrate solution, 183 potassium for oral solution, 224 Ammonia dichlorohydrex polyethylene glycol, 184 potassium tablets, 224 alcoholic TS, 6164 dichlorohydrex propylene glycol, 185 sodium, 225 detector tube, 6074 hydroxide gel, 186 Aminobenzoic acid, 227 N 13 injection, 3150 hydroxide gel, dried, 186 gel, 228 nitrate TS, silver, 6173 hydroxide gel capsules, dried, 187 p-Aminobenzoic acid, 6073 solution, diluted, 6074 hydroxide gel tablets, dried, 187 2-Aminobenzonitrile, 6073 solution, strong, 5569 monostearate, 5565 Aminocaproic acid, 229 spirit, aromatic, 282 oxide, 5567 injection, 229 TS, 6074, 6164 oxide, acid-washed, 6073 oral solution, 230 TS 2, 6165 phosphate gel, 187 tablets, 230 TS alcoholic, 6165 potassium sulfate, 6073
Recommended publications
  • Water Quality Testing Summary

    Water Quality Testing Summary

    WATER QUALITY TESTING SUMMARY A DETAILED REVIEW OF THE TEST RESULTS FOR THE DRINKING WATER PRODUCED BY THE CARY/APEX WATER TREATMENT FACILITY 2020 JOHN CONLEY (Senior Laboratory Analyst) has been employed by the Town of Cary at the Cary/Apex Water Treatment Facility Laboratory since September 2001. CARY/APEX WATER TREATMENT FACILITY 2020 WATER QUALITY TESTING SUMMARY We are pleased to present to you the Cary/ If you have any questions or concerns regarding this Apex Water Treatment Facility Test Result report, please contact Rachel Monschein, Water System Summary for 2020. This report is a snapshot of last Laboratory Supervisor, at (919) 362-5507. year’s water quality. The values contained in this report In order to ensure that tap water is safe to drink, EPA are based on single measurements or yearly averages depending on the contaminant. The Environmental prescribes regulations that limit the amount of certain Protection Agency and/or the State requires us to contaminants in water provided by public water systems. monitor for certain substances less than once per year Drinking water, including bottled water, may reasonably because the concentrations of these substances are not be expected to contain at least small amounts of some expected to vary significantly from year to year. Some of contaminants. The presence of contaminants does not the data, though representative of the water quality, is necessarily indicate the water poses a health risk. To obtain more than one year old. In these cases, the most recent more information about contaminants and potential data is included, along with the year in which the sample health effects, call the EPA’s Safe Drinking Water Hotline was taken.
  • 01 Excipients Prelims 1..9

    01 Excipients Prelims 1..9

    Ethylparaben 1 Nonproprietary Names BP: Ethyl Hydroxybenzoate SEM 1: Excipient: ethylparaben; magnification: 600Â. JP: Ethyl Parahydroxybenzoate PhEur: Ethyl Parahydroxybenzoate E USP-NF: Ethylparaben 2 Synonyms Aethylum hydrobenzoicum; CoSept E; E214; ethylis parahydroxy- benzoas; ethyl p-hydroxybenzoate; Ethyl parasept; 4-hydroxyben- zoic acid ethyl ester; Nipagin A; Solbrol A; Tegosept E; Uniphen P- 23. 3 Chemical Name and CAS Registry Number Ethyl-4-hydroxybenzoate [120-47-8] 4 Empirical Formula and Molecular Weight C9H10O3 166.18 5 Structural Formula SEM 2: Excipient: ethylparaben; magnification: 3000Â. 6 Functional Category Antimicrobial preservative. 7 Applications in Pharmaceutical Formulation or Technology Ethylparaben is widely used as an antimicrobial preservative in cosmetics,(1) food products, and pharmaceutical formulations. It may be used either alone or in combination with other paraben esters or with other antimicrobial agents. In cosmetics it is one of the most frequently used preservatives. The parabens are effective over a wide pH range and have a broad spectrum of antimicrobial activity, although they are most effective against yeasts and molds; see Section 10. Owing to the poor solubility of the parabens, paraben salts, particularly the sodium salt, are frequently used. However, this may cause the pH of poorly buffered formulations to become more alkaline. See Methylparaben for further information. 8 Description Ethylparaben occurs as a white, odorless or almost odorless, active against yeasts and molds than against bacteria. They crystalline powder. are also more active against Gram-positive than against Gram-negative bacteria. 9 Pharmacopeial Specifications The activity of the parabens increases with increasing chain See Table I. See also Section 18. length of the alkyl moiety, but solubility decreases.
  • Early Protective Effects of Tiotropium Bromide in Patients with Airways Hyperres P O N S I V E N E S S

    Early Protective Effects of Tiotropium Bromide in Patients with Airways Hyperres P O N S I V E N E S S

    European Review for Medical and Pharmacological Sciences 2004; 8: 259-264 Early protective effects of tiotropium bromide in patients with airways hyperres p o n s i v e n e s s C. TERZANO, A. PETROIANNI, A. RICCI, L. D’ANTONI, L. ALLEGRA* Department of Cardiovascular and Respiratory Sciences, Respiratory Diseases Unit, Fondazione E. Lorillard Spencer Cenci, “La Sapienza” University - Rome (Italy) *Institute of Respiratory Diseases, University of Milan, Ospedale Maggiore IRCCS – Milan (Italy) Abstract. – Tiotropium is an anticholiner- Introduction gic drug for Ch ronic Obstructive Pulmonary Di sease (COPD) patients, with a peak b ron- Ti o t rop ium is a qu atern a ry amm o niu m chodilator effect observed after 1.5 to 2 hours and a long duration of action. The aim of our co ngener of atropine. It has been developed study was to quantify the early protection of a as a lon g-acting an ticho linergic bro n c h o d i l a- single dose of inhaled tiotropium against metha- tor for inhalation by patients with chronic ob- choline-induced bronchoconstriction in asthmat- s t ructive pu lmon ary d isease (COPD). Dru g ic patients with airway hyperresponsiveness. p ro p e rties o f ant icho lin ergic agent s have Ten subjects (7M, 3F), with history of asthma been well-kno wn to man y cultures for many and a baseline FEV (Forced Expiratory Volume 1 1 1 c e n t u r i e s . In the 1920s the d iscovery o f the sec) >80% of pred icted, were enrolled in the s t u d y.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Laboratory Reagents Product List 2021

    Laboratory Reagents Product List 2021

    PRODUCT LIST Examples of our laboratory reagents Product list – selected products Artificial Urine Brooks and Keevil AMPQ44861.1000 Auramine-Rhodamine AMPQ55029.0500 Below is a selection of products. If you cannot find what you are look- Auric Chloride 0.1% AMPQ12450.0500 ing for, please contact us about your specific requests for laboratory reagents, volume and packaging, etc. Auric Chloride 1% AMPQ12452.0100 We mainly use chemicals by p.a. quality. If you want growth control on growing media, please contact us for an offer. B Balanced Salt Solution for Storage AMPQ46214.0100 Product name Cat. No. Balanced Salt Solution with Tris AMPQ40040.1000 Barium Chloride 0.5 M = 1.0 N AMPQ42099.1000 2,4-Dinitroflouro Benzen 1.3% v/v AMPQ44913.0100 Barium Chloride 1 M AMPQ43551.0500 2-Amino-2-Methyl-1,3-propanediol 2.1 % w/v AMPQ42009.0250 Barium Chloride 10% w/v AMPQ10513.1000 2-Propanol 35% AMPQ12900.5000 Barium Diphenylamine Sulfonate AMPQ40838.0500 Basophil Counting Solution AMPQ90492.0200 A Basophilic Colouring Solution AMPQ42037.0100 Acetate Buffer 0.1 M, pH 4.0 AMPQ10021.1000 Benzamidine 0.5 M in MilliQ H2O AMPQ10750.0100 Acetate Buffer 0.1 M, pH 4.8 AMPQ40728.1000 Benzoe I Colouring Solution AMPQ10779.0100 Acetate Buffer 0.1 M, pH 5.9 AMPQ43009.1000 Benzoe II Colouring Solution AMPQ10781.0100 Acetate Buffer 35%, pH 5.6 AMPQ10015.1000 Biebrich Scarlet Solution AMPQ46088.1000 Acetate Buffer Walpole pH 4.1 AMPQ55005.0500 Biebrich's Scarlet Acid Fuchsin AMPQ29082.0500 Acetic Acid 0.1 M Titrated AMPQ11590.5000 Bies Colouring Solution AMPQ10780.0050 Acetic Acid 1% AMPQ11515.1000 BiGGY Agar AMPQ02048.0015 Acetic Acid 10% P.A.
  • Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Drug-Induced Anaphylaxis in China: a 10 Year Retrospective Analysis of The

    Int J Clin Pharm DOI 10.1007/s11096-017-0535-2 RESEARCH ARTICLE Drug‑induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database Ying Zhao1,2,3 · Shusen Sun4 · Xiaotong Li1,3 · Xiang Ma1 · Huilin Tang5 · Lulu Sun2 · Suodi Zhai1 · Tiansheng Wang1,3,6 Received: 9 May 2017 / Accepted: 19 September 2017 © The Author(s) 2017. This article is an open access publication Abstract Background Few studies on the causes of (50.1%), mucocutaneous (47.4%), and gastrointestinal symp- drug-induced anaphylaxis (DIA) in the hospital setting are toms (31.3%). A total of 249 diferent drugs were involved. available. Objective We aimed to use the Beijing Pharma- DIAs were mainly caused by antibiotics (39.3%), traditional covigilance Database (BPD) to identify the causes of DIA Chinese medicines (TCM) (11.9%), radiocontrast agents in Beijing, China. Setting Anaphylactic case reports from (11.9%), and antineoplastic agents (10.3%). Cephalospor- the BPD provided by the Beijing Center for Adverse Drug ins accounted for majority (34.5%) of antibiotic-induced Reaction Monitoring. Method DIA cases collected by the anaphylaxis, followed by fuoroquinolones (29.6%), beta- BPD from January 2004 to December 2014 were adjudi- lactam/beta-lactamase inhibitors (15.4%) and penicillins cated. Cases were analyzed for demographics, causative (7.9%). Blood products and biological agents (3.1%), and drugs and route of administration, and clinical signs and plasma substitutes (2.1%) were also important contributors outcomes. Main outcome measure Drugs implicated in DIAs to DIAs. Conclusion A variety of drug classes were impli- were identifed and the signs and symptoms of the DIA cases cated in DIAs.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Page 1 Note: Within Nine Months from the Publication of the Mention

    Page 1 Note: Within Nine Months from the Publication of the Mention

    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
  • Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’

    Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’

    0270.6474/85/0505-1202$02.00/O The Journal of Neuroscience CopyrIght 0 Society for Neuroscrence Vol. 5, No. 5, pp. 1202-1207 Printed in U.S.A. May 1985 Pharmacological and Ionic Characterizations of the Muscarinic Receptors Modulating [3H]Acetylcholine Release from Rat Cortical Synaptosomes’ EDWIN M. MEYER* AND DEBORAH H. OTERO Department of Pharmacology and Therapeutics, University of Florida School of Medicine, Gainesville, Florida 32610 Abstract brain (Gonzales and Crews, 1984). M,-receptors, however, appear pre- and postsynaptically in brain, are regulated by an intrinsic The muscarinic receptors that modulate acetylcholine membrane protein that binds to GTP (g-protein), and may not be release from rat cortical synaptosomes were characterized coupled to changes in phosphatidylinositol turnover. with respect to sensitivity to drugs that act selectively at M, The present studies were designed to determine whether M,- or or Ma receptor subtypes, as well as to changes in ionic Mp-receptors mediate the presynaptic modulation of ACh release. strength and membrane potential. The modulatory receptors These studies involve dose-response curves for the release of appear to be of the M2 type, since they are activated by synaptosomal [3H]ACh in the presence of selected muscarinic ago- carbachol, acetylcholine, methacholine, oxotremorine, and nists and antagonists, as well as treatments that selectively alter MI- bethanechol, but not by pilocarpine, and are blocked by or M,-receptor activity. Our results indicate that the presynaptic atropine, scopolamine, and gallamine (at high concentra- modulation of [3H]ACh release is mediated by MP- but not MI- tions), but not by pirenzepine or dicyclomine.
  • A Wet Process for the Extraction of Mercury

    A Wet Process for the Extraction of Mercury

    Scholars' Mine Professional Degree Theses Student Theses and Dissertations 1916 A wet process for the extraction of mercury Robert Glenn Sickly Follow this and additional works at: https://scholarsmine.mst.edu/professional_theses Part of the Metallurgy Commons Department: Recommended Citation Sickly, Robert Glenn, "A wet process for the extraction of mercury" (1916). Professional Degree Theses. 140. https://scholarsmine.mst.edu/professional_theses/140 This Thesis - Open Access is brought to you for free and open access by Scholars' Mine. It has been accepted for inclusion in Professional Degree Theses by an authorized administrator of Scholars' Mine. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for redistribution requires the permission of the copyright holder. For more information, please contact [email protected]. "/389 A '.vET PROCESS FOR THE EXTRACTION OF MERCURY. ROBERT GLENN SICKLY. '~~****** A THESIS subl!li tted to the facul t Jr of the SCHOOL OF lnIN}~S AND METALI.. URGY O~' THE U:nlv~RSITY OF I~ISSOURI in partial fulfillment of the work required for the Degree of METALJJURGICAL :S:NGINEER. Cobalt, Ont. Canada. 1916. ********* Approved by Professor 0 r~· w-e-r-~r~~J#/d' £7' 11/6 TABLE OF COIrTE1:ITS. Subject. Pa.ge. Introduction ------------------------~---------- 2. The nature o~ the mercury losses --------------- 2. The chemical loss o~ mercury ------------------- 3. The mercury process ---------------------------- 5. Flow-sheet ------------------------------------- 7. Chemistry of the process ----------------------- 7. hlethod of dissolving the mercury --------------- 8: Various methods of precipitation --------------- 16. Aluminium precipitation ------------------------ 19. Curve on aluminium precipitation ----------- opp. 21. Experimental plant installation ---------------- 23. Curves on operation of experimental plant --GpP.
  • ACR Manual on Contrast Media

    ACR Manual on Contrast Media

    ACR Manual On Contrast Media 2021 ACR Committee on Drugs and Contrast Media Preface 2 ACR Manual on Contrast Media 2021 ACR Committee on Drugs and Contrast Media © Copyright 2021 American College of Radiology ISBN: 978-1-55903-012-0 TABLE OF CONTENTS Topic Page 1. Preface 1 2. Version History 2 3. Introduction 4 4. Patient Selection and Preparation Strategies Before Contrast 5 Medium Administration 5. Fasting Prior to Intravascular Contrast Media Administration 14 6. Safe Injection of Contrast Media 15 7. Extravasation of Contrast Media 18 8. Allergic-Like And Physiologic Reactions to Intravascular 22 Iodinated Contrast Media 9. Contrast Media Warming 29 10. Contrast-Associated Acute Kidney Injury and Contrast 33 Induced Acute Kidney Injury in Adults 11. Metformin 45 12. Contrast Media in Children 48 13. Gastrointestinal (GI) Contrast Media in Adults: Indications and 57 Guidelines 14. ACR–ASNR Position Statement On the Use of Gadolinium 78 Contrast Agents 15. Adverse Reactions To Gadolinium-Based Contrast Media 79 16. Nephrogenic Systemic Fibrosis (NSF) 83 17. Ultrasound Contrast Media 92 18. Treatment of Contrast Reactions 95 19. Administration of Contrast Media to Pregnant or Potentially 97 Pregnant Patients 20. Administration of Contrast Media to Women Who are Breast- 101 Feeding Table 1 – Categories Of Acute Reactions 103 Table 2 – Treatment Of Acute Reactions To Contrast Media In 105 Children Table 3 – Management Of Acute Reactions To Contrast Media In 114 Adults Table 4 – Equipment For Contrast Reaction Kits In Radiology 122 Appendix A – Contrast Media Specifications 124 PREFACE This edition of the ACR Manual on Contrast Media replaces all earlier editions.
  • An End-To-End Workflow for Quantitative Screening of Multiclass, Multiresidue Veterinary Drugs in Meat Using the Agilent 6470 Triple Quadrupole LC/MS

    An End-To-End Workflow for Quantitative Screening of Multiclass, Multiresidue Veterinary Drugs in Meat Using the Agilent 6470 Triple Quadrupole LC/MS

    Application Note Food Testing & Agriculture An End-To-End Workflow for Quantitative Screening of Multiclass, Multiresidue Veterinary Drugs in Meat Using the Agilent 6470 Triple Quadrupole LC/MS Authors Abstract Siji Joseph, Aimei Zou, Chee A comprehensive LC/MS/MS workflow was developed for targeted screening or Sian Gan, Limian Zhao, and quantitation of 210 veterinary drug residues in animal muscle prepared for human Patrick Batoon consumption, with the intention to accelerate and simplify routine laboratory testing. Agilent Technologies, Inc. The workflow ranged from sample preparation through chromatographic separation, MS detection, data processing and analysis, and report generation. The workflow performance was evaluated using three muscle matrices—chicken, pork, and beef— and was assessed on two different Agilent triple quadrupole LC/MS models (an Agilent 6470 and a 6495C triple quadrupole LC/MS). A simple sample preparation protocol using Agilent Captiva EMR—Lipid cartridges provided efficient extraction and matrix cleanup. A single chromatographic method using Agilent InfinityLab Poroshell 120 EC-C18 columns with a 13-minute method delivered acceptable separation and retention time distribution across the elution window for reliable triple quadrupole detection and data analysis. Workflow performance was evaluated based on evaluation of limit of detection (LOD), limit of quantitation (LOQ), calibration curve linearity, accuracy, precision, and recovery, using matrix-matched spike samples for a range from 0.1 to 100 μg/L. Calibration curves were plotted from LOQ to 100 μg/L, where all analytes demonstrated linearity R2 >0.99. Instrument method accuracy values were within 73 to 113%. Target analytes response and retention time %RSD values were ≤19% and ≤0.28% respectively.